-
Something wrong with this record ?
Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier
P. Pavek, T. Smutny,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Biological Transport physiology MeSH
- Biotransformation physiology MeSH
- Enzymes metabolism MeSH
- Pharmaceutical Preparations metabolism MeSH
- Humans MeSH
- Placenta metabolism MeSH
- Receptors, Cytoplasmic and Nuclear metabolism MeSH
- Pregnancy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Over the past 20 years, the toxicological and protective roles of the placental barrier with respect to drug detoxification and transporter-controlled protection of the fetus have been intensively examined. Several cytochrome P450 enzymes are expressed in placental trophoblast at different stages of pregnancy, though only a few of these have functional activity to metabolize xenobiotics. Drug transporters such as P-glycoprotein/MDR1 or breast cancer resistance protein (BCRP) are highly expressed in the placenta, and their functional activities have been demonstrated in the placenta both in vitro and in vivo. In addition, several studies have reported on ligand-activated transcription factors and nuclear receptors referred to as "xenosensors" in the placenta. The xenosensors control transcriptional regulation of both xenobiotic-metabolizing enzymes and drug transporters in different organs. Their ligands include toxic compounds and environmental pollutants, drugs, as well as herbal, dietary or vitamin supplements. Nevertheless, it remains debatable whether the placental barrier adapts to toxic injuries coming either from maternal medication or environmental contamination and whether the placenta contains a mechanism to respond dynamically in protecting the developing fetus. In the present paper, we summarize current knowledge about the activity and expression of major ligand-activated transcriptional mechanisms involved in biotransformation enzymes and transporters regulation in human placenta. In particular, we highlight the emerging roles of aryl hydrocarbon (AHR), vitamin D (VDR), glucocorticoid (GR) and pregnane X (PXR) receptors in that regulation. We show that the placenta constitute a unique metabolizing organ with significant overlap of exogenous and endogenous compounds metabolism controlled by nuclear receptors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074666
- 003
- CZ-PrNML
- 005
- 20141007113522.0
- 007
- ta
- 008
- 141006s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/03602532.2013.835819 $2 doi
- 035 __
- $a (PubMed)24020384
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Centre for Drug Development, Charles University in Prague , Hradec Kralove , Czech Republic.
- 245 10
- $a Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier / $c P. Pavek, T. Smutny,
- 520 9_
- $a Over the past 20 years, the toxicological and protective roles of the placental barrier with respect to drug detoxification and transporter-controlled protection of the fetus have been intensively examined. Several cytochrome P450 enzymes are expressed in placental trophoblast at different stages of pregnancy, though only a few of these have functional activity to metabolize xenobiotics. Drug transporters such as P-glycoprotein/MDR1 or breast cancer resistance protein (BCRP) are highly expressed in the placenta, and their functional activities have been demonstrated in the placenta both in vitro and in vivo. In addition, several studies have reported on ligand-activated transcription factors and nuclear receptors referred to as "xenosensors" in the placenta. The xenosensors control transcriptional regulation of both xenobiotic-metabolizing enzymes and drug transporters in different organs. Their ligands include toxic compounds and environmental pollutants, drugs, as well as herbal, dietary or vitamin supplements. Nevertheless, it remains debatable whether the placental barrier adapts to toxic injuries coming either from maternal medication or environmental contamination and whether the placenta contains a mechanism to respond dynamically in protecting the developing fetus. In the present paper, we summarize current knowledge about the activity and expression of major ligand-activated transcriptional mechanisms involved in biotransformation enzymes and transporters regulation in human placenta. In particular, we highlight the emerging roles of aryl hydrocarbon (AHR), vitamin D (VDR), glucocorticoid (GR) and pregnane X (PXR) receptors in that regulation. We show that the placenta constitute a unique metabolizing organ with significant overlap of exogenous and endogenous compounds metabolism controlled by nuclear receptors.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a biologický transport $x fyziologie $7 D001692
- 650 _2
- $a biotransformace $x fyziologie $7 D001711
- 650 _2
- $a enzymy $x metabolismus $7 D004798
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a léčivé přípravky $x metabolismus $7 D004364
- 650 _2
- $a placenta $x metabolismus $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a receptory cytoplazmatické a nukleární $x metabolismus $7 D018160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Smutny, Tomas
- 773 0_
- $w MED00001447 $t Drug metabolism reviews $x 1097-9883 $g Roč. 46, č. 1 (2014), s. 19-32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24020384 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20141007114000 $b ABA008
- 999 __
- $a ok $b bmc $g 1042549 $s 873578
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 46 $c 1 $d 19-32 $i 1097-9883 $m Drug metabolism reviews $n Drug Metab Rev $x MED00001447
- LZP __
- $a Pubmed-20141006